She has resigned from the former; the latter does not matter since 23andMe’s equity could be wiped out. If persistence pays off, a company that started out as little more than an intriguing idea and a ...
American International Group Inc.'s successful bid to avoid covering litigation against opioid manufacturing giant ...
The global extended release drugs market is experiencing significant growth, projected to expand at a robust 11% CAGR from 2022 to 2032. With a valuation of USD 48 billion in 2022, the market is ...
Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S.
Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.
Mallinckrodt, the Irish pharmaceutical company with its U.S. headquarters in Hazelwood, has agreed to merge with drug maker ...
When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc.
Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ETCompany ParticipantsLaure Park - Senior Vice President ...
Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...
The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...